Document Detail


"Blockade Of Renin Angiotensin System In Heart Failure Post-Myocardial Infarction: What Is The Best Therapy?"
MedLine Citation:
PMID:  24993597     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Heart Failure (HF) is a progressive and fatal disorder, which ranks among the major public health problems in Brazil and worldwide. However, survival for patients who developed the syndrome after myocardial infarction (MI) enhanced significantly, as a result of an improvement of pharmacological therapies. A medical breakthrough was the discovery that remodelling of the left ventricle (LV) may be limited by the blockade of the renin-angiotensin system (RAS), at the level of angiotensin converting enzyme (ACE) and binding of angiotensin (Ang) II to its AT1 receptor. This review shows that the therapeutic effects of both ACE inhibitors and the angiotensin receptor blockers (ARB) go beyond the interference in the biochemical pathway ACE-Ang II AT1-receptor. Such effects are also related to the potentiation of bradykinin and increased beneficial effects mediated by the AT2 receptor. Therefore, the results of five randomized trials were presented, which evaluated the use of losartan, valsartan or candesartan, considering their effects on survival and risk of clinical deterioration in patients with symptomatic HF after MI. These studies confirmed the advantage of ARBs over inhibitors in case of cough, rashes and angioneurotic edema, despite similar adverse effects, such as hyperkalemia, renal failure and hypotension. Thus, ACE inhibitors also appear as the first option as RAS inhibitors in search of relevant results for the patient, allowing the alternative use of ARBs to those patients with intolerance.
Authors:
Caio Eduardo Gullo; Victor Andre de Almeida Zia; Jose Fernando Vilela-Martin
Related Documents :
14728077 - Prevention of cardiac cell injury during acute myocardial infarction: possible role for...
12124217 - Cardioselective overexpression of ho-1 prevents i/r-induced cardiac dysfunction and apo...
16926367 - Neurogenic pulmonary edema due to traumatic brain injury: evidence of cardiac dysfunction.
1756137 - Do neutrophils contribute to myocardial stunning?
19121567 - Feasibility of prediction of myocardial viability with doppler tissue imaging following...
21172497 - Three-dimensional echocardiography for the preoperative assessment of patients with lef...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-02
Journal Detail:
Title:  Recent patents on cardiovascular drug discovery     Volume:  -     ISSN:  2212-3962     ISO Abbreviation:  Recent Pat Cardiovasc Drug Discov     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101263805     Medline TA:  Recent Pat Cardiovasc Drug Discov     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Distortion correction and calibration of intra-operative spine X-ray images using a constrained DLT ...
Next Document:  DFT examination of rare ?-SiMe3 abstraction in Ta(NMe2)4[N(SiMe3)2]: formation of the imide compound...